Bromodomains and Their Pharmacological Inhibitors
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Over 60 bromodomains belonging to proteins with very different functions have been identified in humans. Several of them interact with acetylated lysine residues, leading to the recruitment and stabilization of protein complexes. The bromodomain and extra‐terminal domain (BET) proteins contain tandem bromodomains which bind to acetylated histones and are thereby implicated in a number of DNA‐centered processes, including the regulation of gene expression. The recent identification of inhibitors of BET and non‐BET bromodomains is one of the few examples in which effective blockade of a protein–protein interaction can be achieved with a small molecule. This has led to major strides in the understanding of the function of bromodomain‐containing proteins and their involvement in diseases such as cancer and inflammation. Indeed, BET bromodomain inhibitors are now being clinically evaluated for the treatment of hematological tumors and have also been tested in clinical trials for the relatively rare BRD‐NUT midline carcinoma. This review gives an overview of the newest developments in the field, with a focus on the biology of selected bromodomain proteins on the one hand, and on reported pharmacological inhibitors on the other, including recent examples from the patent literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
Regulation of nucleosome dynamics by histone modifications
Zentner, G. E., & Henikoff, S. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2470 · Cited by 923
Jin, Q., Yu, L., Wang, L., Zhang, Z., Kasper, L. H., Lee, J., Wang, C., Brindle, P. K., Dent, S. Y. R., & Ge, K. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.318 · Cited by 877
Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532
Cooperative binding of two acetylation marks on a histone tail by a single bromodomain
Morinière, J., Rousseaux, S., Steuerwald, U., Soler-López, M., Curtet, S., Vitte, A.-L., Govin, J., Gaucher, J., Sadoul, K., Hart, D. J., et al. (2009) · Nature · doi:10.1038/nature08397 · Cited by 469
Ivanov, A. V., Peng, H., Yurchenko, V., Yap, K. L., Negorev, D. G., Schultz, D. C., Psulkowski, E., Fredericks, W. J., White, D. E., Maul, G. G., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.012 · Cited by 432
BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406
KAP1 Protein: An Enigmatic Master Regulator of the Genome
Iyengar, S., & Farnham, P. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.252569 · Cited by 367
Houzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292
Emerging roles for chromatin as a signal integration and storage platform
Badeaux, A. I., & Shi, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3545 · Cited by 291
BET proteins promote efficient murine leukemia virus integration at transcription start sites
Sharma, A., Larue, R. C., Plumb, M. R., Malani, N., Male, F., Slaughter, A., Kessl, J. J., Shkriabai, N., Coward, E., Aiyer, S. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307157110 · Cited by 193
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185
Guetg, C., Lienemann, P., Sirri, V., Grummt, I., Hernandez‐Verdun, D., Hottiger, M. O., Fussenegger, M., & Santoro, R. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.17 · Cited by 184
BET acetyl-lysine binding proteins control pathological cardiac hypertrophy
Spiltoir, J. I., Stratton, M. S., Cavasin, M. A., Demos-Davies, K., Reid, B. G., Qi, J., Bradner, J. E., & McKinsey, T. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.07.017 · Cited by 174
Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouse
Shang, E., Wang, X., Wen, D., Greenberg, D. A., & Wolgemuth, D. J. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21911 · Cited by 156
Epigenetic flexibility in metabolic regulation: disease cause and prevention
Kirchner, H., Osler, M. E., Krook, A., & Zierath, J. R. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.11.008 · Cited by 143
Sexual dimorphisms in zonal gene expression in mouse liver
Saito, K., Negishi, M., & James Squires, E. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.025 · Cited by 36
Cited by
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Histone Modifications and Cancer
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Palmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00405 · Cited by 168
Characteristic roadmap of linker governs the rational design of PROTACs
Dong, Y., Ma, T., Xu, T., Feng, Z., Li, Y., Song, L., Yao, X., Ashby, C. R., & Hao, G.-F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.007 · Cited by 146
Metadata
- Authors
- Gallenkamp, D., Gelato, K. A., Haendler, B., & Weinmann, H.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2014-02-04
- Volume
- 9
- Issue
- 3
- Pages
- 438-464
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2083627942
- Cited by
- 122
- References
- 24
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.